The effectiveness of nirmatrelvir-ritonavir and molnupiravir for the treatment of COVID-19 among US veterans medrxivpreprint OHSUNews YaleMed UMich HopkinsMedicine COVID19 coronavirus covid veterans antiviral
By Neha MathurDec 13 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to the medRxiv* server, researchers evaluated the effectiveness of severe acute respiratory syndrome coronavirus 2 antivirals, nirmatrelvir-ritonavir, and molnupiravir among Veterans in the United States of America .
However, these RCTs implemented among unvaccinated participants prior to the advent of Omicron did not evaluate the outcomes of these antivirals after 29 days following SARS-CoV-2 infection. Also, they collated no data on post-acute sequelae of SARS-CoV-2 infection . As new SARS-CoV-2 VOCs continue to emerge, it is crucial to determine the effect of these antivirals in an ethnically diverse population with more comorbidities.
The team developed three cohorts with the VHA participants; the first group received nirmatrelvir-ritonavir vs. no treatment, and the second and third groups received molnupiravir vs. no treatment and molnupiravir vs. nirmatrelvir-ritonavir treatment, respectively. Study findings Nirmatrelvir-ritonavir effectively reduced the risk of hospitalization and all-cause mortality by 47% in the 30-day follow-up period among 1587 veterans. Compared to matched controls who received a placebo, the risk difference for hospitalization and death in nirmatrelvir-ritonavir-treated patients were 13.97 and -11.71, respectively.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The benefit-risk of the mRNA-1273 COVID-19 vaccineThe benefit-risk of the mRNA-1273 COVID-19 vaccine medrxivpreprint US_FDA mRNA vaccine vaccination COVID19 coronavirus covid SARSCoV2
Read more »
Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infectionBioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection biorxivpreprint NorthwesternU ChariteBerlin UChicago brain SARSCoV2 ACE2 COVID19 coronavirus covid
Read more »
What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals?What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals? medrxivpreprint UUtah UCSF DukeMedSchool nyugrossman symptoms riskfactor longcovid covid COVID19 SARSCoV2
Read more »
How the COVID-19 pandemic impacted the treatment pancreatic cancer patientsHow the COVID-19 pandemic impacted the treatment pancreatic cancer patients Cancer Coronavirus Disease COVID PancreaticCancer Pandemic medrxivpreprint OpenSAFELY UniOfSurrey UniofOxford ucl
Read more »
SARS-CoV-1 and SARS-CoV-2 spike proteins utilize different mechanisms to bind to ACE2SARS-CoV-1 and SARS-CoV-2 spike proteins utilize different mechanisms to bind to ACE2 ACE2 Angiotensin Coronavirus COVID MERSCoV SARSCoV2 FrontMicrobiol UTEP HowardU
Read more »
What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir? JAMANetworkOpen virus COVID19 coronavirus covid antivirals antiviral SARSCoV2
Read more »